69Summary: A new study reports T cells are activated in the intestines and migrate to the brain, causing an inflammatory cascade that may lead to multiple sclerosis. Researchers say the gut microbiome may play a more significant role in the development and progression of MS than previously believed.Source: University of Zurich.Multiple sclerosis is an autoimmune disease in which the body’s own immune system attacks and damages the protective coating around nerve cells. This coating is made up of myelin – a biological membrane of protein and fatty substances – which is why research efforts to find the disease’s target antigen have so far focused on the myelin membrane’s components. New findings made by the research group of Mireia Sospedra and Roland Martin from the University of Zurich’s Clinical Research Priority Program Multiple Sclerosis now suggest that it is worth broadening the research perspective to gain a better understanding of the pathological processes.Inflammatory cascadeIn the journal Science Translational Medicine, the scientists report that T cells – i.e. the immune cells responsible for pathological processes – react to a protein called GDP-L-fucose synthase. This enzyme is formed in human cells as well as in bacteria frequently found in the gastrointestinal flora of patients suffering from multiple sclerosis. “We believe that the immune cells are activated in the intestine and then migrate to the brain, where they cause an inflammatory cascade when they come across the human variant of their target antigen,” says Mireia Sospedra.Diminishing myelin sheaths: The damaged areas (at the bottom of the image) of the brains of MS patients lack myelin (at the top, in blue). NeuroscienceNews.com image is credited to Dr. med. Imke Metz, University of Göttingen, Germany.For the genetically defined subgroup of MS patients examined by the researchers, results show that gut microbiota could play a far greater role in the pathogenesis of the disease than previously assumed. Mireia Sospedra hopes that these findings can soon also be translated into therapy; she plans to test the immunoactive components of GDP-L-fucose synthase using an approach that the researchers have been pursuing for several years already.Re-educating the immune system“Our clinical approach specifically targets the pathological autoreactive immune cells,” says Sospedra. This approach therefore differs radically from other treatments that are currently available, which throttle the whole immune system. While these treatments often succeed in stopping the progression of the disease, they also weaken the immune system – and can thus cause severe side effects.The clinical approach of the research group involves drawing blood from MS patients in a clinical trial and then attaching the immunoactive protein fragments onto the surface of red blood cells in a laboratory. When the blood is reintroduced into the bloodstream of patients, the fragments help to “re-educate” their immune system and make it “tolerate” its own brain tissue. This therapeutic approach aims for effective targeted treatment without severe side effects.[divider]About this neuroscience research article[/divider]Source: Mireia Sospedra Ramos – University of Zurich Publisher: Organized by NeuroscienceNews.com. Image Source: NeuroscienceNews.com image is credited to Dr. med. Imke Metz, University of Göttingen, Germany. Original Research: Abstract for “GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3*02:02 patients with multiple sclerosis” by Raquel Planas, Radleigh Santos, Paula Tomas-Ojer, Carolina Cruciani, Andreas Lutterotti, Wolfgang Faigle, Nicole Schaeren-Wiemers, Carmen Espejo, Herena Eixarch, Clemencia Pinilla, Roland Martin and Mireia Sospedra in Science Translational Medicine. Published October 10 2018. doi:10.1126/scitranslmed.aat4301[divider]Cite This NeuroscienceNews.com Article[/divider]See alsoFeaturedGeneticsNeuroscienceOpen Neuroscience ArticlesPsychology·March 9, 2020The largest genetic map of psychiatric disorders so far[cbtabs][cbtab title=”MLA”]University of Zurich”Link Between Gut Flora and Multiple Sclerosis Discovered.” NeuroscienceNews. NeuroscienceNews, 11 October 2018. <https://neurosciencenews.com/multiple-sclerosis-gut-flora-10003/>.[/cbtab][cbtab title=”APA”]University of Zurich(2018, October 11). Link Between Gut Flora and Multiple Sclerosis Discovered. NeuroscienceNews. Retrieved October 11, 2018 from https://neurosciencenews.com/multiple-sclerosis-gut-flora-10003/[/cbtab][cbtab title=”Chicago”]University of Zurich”Link Between Gut Flora and Multiple Sclerosis Discovered.” https://neurosciencenews.com/multiple-sclerosis-gut-flora-10003/ (accessed October 11, 2018).[/cbtab][/cbtabs]AbstractGDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3*02:02 patients with multiple sclerosisMultiple sclerosis is an immune-mediated autoimmune disease of the central nervous system that develops in genetically susceptible individuals and likely requires environmental triggers. The autoantigens and molecular mimics triggering the autoimmune response in multiple sclerosis remain incompletely understood. By using a brain-infiltrating CD4+ T cell clone that is clonally expanded in multiple sclerosis brain lesions and a systematic approach for the identification of its target antigens, positional scanning peptide libraries in combination with biometrical analysis, we have identified guanosine diphosphate (GDP)–L-fucose synthase as an autoantigen that is recognized by cerebrospinal fluid–infiltrating CD4+ T cells from HLA-DRB3*–positive patients. Significant associations were found between reactivity to GDP-L-fucose synthase peptides and DRB3*02:02 expression, along with reactivity against an immunodominant myelin basic protein peptide. These results, coupled with the cross-recognition of homologous peptides from gut microbiota, suggest a possible role of this antigen as an inducer or driver of pathogenic autoimmune responses in multiple sclerosis.[divider]Feel free to share this Neuroscience News.[/divider]Join our Newsletter I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.comWe hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.